Miltenyi Biotec in the news

This webinar, presented by Miltenyi Biotec, explores the applications and analysis of bulk T-cell receptor repertoire sequencing to advance immunology research and biomarker discovery.

Miltenyi Biotec is organizing a webinar on the isolation and application of primary human alveolar cells for lung disease research and regenerative medicine.

The article discusses advancements in cell sorting technologies by various companies, focusing on improved precision, scalability, and user-friendliness for research and clinical applications.

Miltenyi Biotec is investing ten million euros in a new production facility in Teterow to expand manufacturing for its cancer and autoimmune disease therapies, creating 50 new jobs, while facing challenges from fluctuating US customs policies and advocating for better regional infrastructure.

Miltenyi Biotec is transforming into an independent pharmaceutical player by scaling its automated cell therapy production and pursuing global market approval for its own gene-based medicines.

Miltenyi Biotec is expanding its infrastructure and seeking drug approvals to transition from a biotech supplier to a commercial provider of living cell therapies.

Modernization of a Cologne production facility into a high-tech cell and gene therapy hub using digital modeling and sustainable energy systems.

Miltenyi Biotec is renovating a 12,000-square-meter facility in Cologne to significantly expand its production capacity for clinical reagents used in cell and gene therapies.

Miltenyi Biotec is expanding its Cologne site by converting an existing building into a modern production facility for clinical reagents to support growing global cell therapy needs.

Modernization of a former pharmaceutical complex in Cologne into a clinical reagent production facility to meet growing cell and gene therapy demands.

Expansion of clinical reagent manufacturing capacity in Cologne through the renovation of a 12,000 square meter facility scheduled for completion in 2026.

Miltenyi Biotec is expanding its Cologne site to increase manufacturing capacity for clinical reagents and gene therapy products.

Expanding production capacity by renovating a 12,000 sqm former pharmaceutical building in Cologne for clinical reagents by 2026.

Miltenyi Biotec is expanding its Cologne production site through a large-scale renovation of a former pharmaceutical complex to boost manufacturing capacity for clinical reagents.

The company is expanding its Cologne production site by renovating a former pharmaceutical facility to increase clinical reagent manufacturing for cell and gene therapies.

Miltenyi Biotec is renovating a 12,000-square-meter facility in Cologne to expand production of clinical reagents for cell and gene therapies by late 2026.

Cha Biotech is partnering with Miltenyi Biotec to leverage its viral vector platform and automated manufacturing for new CAR-NK cancer treatments.

Markus Weiss has been promoted to Executive Vice President at Miltenyi Biotec to lead North American business units and logistics expansion.

Miltenyi Biotec is ranked as a top German biotechnology company and a global leader in cell separation technology.

Miltenyi Biotec is expanding cell and gene therapy access in India and APAC by building manufacturing infrastructure and training skilled talent through strategic partnerships.